Clinical Trial Update: Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Fruquintinib in combination with Sintilimab for advanced endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Hutchmed | Conditions: Advanced Endometrial Cancer | Phase 3 | Status: RECRUITING